Publications
2017
Huik, Kristi; Soodla, Pilleriin; Pauskar, Merit; Rajasaar, Heli; Jõgeda, Ene-Ly; Eveli, Kallas; Avi, Radko; Lutsar, Irja The evalation of two HIV-1 incidence assays in subjects infected with non-B subtype viruses. ECCMID 2017
2016
Laisaar, Kaja-Triin; Raag, Mait; Lutsar, Irja; Uusküla, Anneli People living with HIV in Estonia: engagement in HIV care in 2013. Euro Surveill. 2016 Oct 27;21(43)
Avi, Radko; Pauskar, Merit; Karki, Tõnis; Kallas, Eveli; Jõgeda, Ene-Ly; Margus, Tõnu; Huik, Kristi; Lutsar, Irja (2016). Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia. Journal of Medical Virology, 88 (3), 448−454, 10.1002/jmv.24361.
Kallas, Eveli; Huik, Kristi; Türk, Silver; Pauskar, Merit; Jõgeda, Ene-Ly; Šunina, Marina; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja (2016). T Cell Distribution in Relation to HIV/HBV/HCV Coinfections and Intravenous Drug Use. Viral immunology, 0−0.
Huik, Kristi; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Jõgeda, Ene-Ly; Karki, Tõnis; Rüütel, Kristi; Talu, Ave; Abel-Ollo, Katri; Uusküla, Anneli; Carrillo, Andrew; Ahuja, Sunil K; He, Weijing; Lutsar, Irja (2016). A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject Drugs. PloS one, 11 (6), e0156850−e0156850, 10.1371/journal.pone.0156850.
Jõgeda, Ene-Ly; Avi, Radko; Pauskar, Merit; Kallas, Eveli; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Lutsar, Irja; Huik, Kristi (2016). Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 43, 83−85, 10.1016/j.meegid.2016.05.022.
2015
Kallas, Eveli; Huik, Kristi; Türk, Silver; Pauskar, Merit; Jõgeda, Ene-Ly; Šunina, Marina; Karki, Tõnis; Des Jarlais, Don; Uusküla, Anneli; Avi, Radko; Lutsar, Irja (2015). Differences in T cell distribution and CCR5 expression in HIV-positive and HIV-exposed seronegative persons who inject drugs. Medical microbiology and immunology, 1−9, 10.1007/s00430-015-0444-8.
Rhee, S.-Y.; Blanco, J.L.; Jordan, M.R.; Taylor, J.; Lemey, P.; Varghese, V.; Hamers, R.L.; Bertagnolio, S.; de Wit, T.F.R.; Aghokeng, A.F.; Albert, J.; Avi, R.; Avila-Rios, S.; Bessong, P.O.; Brooks, J.I.; Boucher, C.A.B.; Brumme, Z.L.; Busch, M.P.; Bussmann, H.; Chaix, M.-L.; Chin, B.S.; DâAquin, T.T.; De Gascun, C.F.; Derache, A.; Descamps, D.; Deshpande, A.K.; Djoko, C.F.; Eshleman, S.H.; Fleury, H.; Frange, P.; Fujisaki, S.; Harrigan, P.R.; Hattori, J.; Holguin, A.; Hunt, G.M.; Ichimura, H.; Kaleebu, P.; Katzenstein, D.; Kiertiburanakul, S.; Kim, J.H.; Kim, S.S.; Li, Y.; Lutsar, I.; Morris, L.; Ndembi, N.; NG, K.P.; Paranjape, R.S.; Peeters, M.; Poljak, M.; Price, M.A.; Ragonnet-Cronin, M.L.; Reyes-Terán, G.; Rolland, M.; Sirivichayakul, S.; Smith, D.M.; Soares, M.A.; Soriano, V.V.; Ssemwanga, D.; Stanojevic, M.; Stefani, M.A.; Sugiura, W.; Sungkanuparph, S.; Tanuri, A.; Tee, K.K.; Truong, H.-H.M.; van de Vijver, D.A.M.C.; Vidal, N.; Yang, C.; Yang, R.; Yebra, G.; Ioannidis, J.P.A.; Vandamme, A.-M.; Shafer, R.W. (2015). Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis (PLoS Medicine). PLOS Medicine, 12(4), 1001810
Soodla P, Rajasaar H, Avi R, Zilmer K, Kink K, Novikova L, Huik K, Maimets M, Lutsar I. Design and structure of the Estonian HIV Cohort Study (E-HIV).Infect Dis (Lond). 2015;47(11):768-75. doi: 10.3109/23744235.2015.1061203.
Kallas, E.; Huik, K.; Pauskar, M.; Jõgeda,E.-L.; Karki, T.; Des Jarlais, D.; Uusküla, A.; Avi, R.; Lutsar, I. (2015). Influence of interleukin 10 polymorphisms -592 and -1082 to the HIV, HBV and HCV serostatus among intravenous drug users. Infection, genetics and evolution, 30, 175 – 180.
2014
Avi, R; Huik, K; Pauskar, M; Ustina, V; Karki,T; Kallas, E; Jõgeda, EL; Krispin, T; Lutsar, I (2014). Transmitted drug resistance is still low in newly diagnosed human immunodeficiency virus type 1 CRF06_cpx-infected patients in Estonia in 2010. AidsResearch and Human Retroviruses, 30(3), 278 – 283.
Huik, K.; Avi, R.; Uibopuu, H.; Pauskar, M.; Margus, T.; Karki, T.; Krispin, T.; Kool, P.; Rüütel, K.; Talu, A.; Abel-Ollo, K.; Uusküla, A.; Carrillo, AQ.; He, W.; Ahuja, SK.; Lutsar, I. (2014). Association between HIV-1 tropism and CCR5 human haplotype E in a Caucasian population. Jaids-Journal of Acquired Immune Deficiency Syndromes, 66(3), 239 – 244.
2013
Huik, K; Avi, R; Pauskar, M; Kallas, E;Jõgeda, EL; Karki, T; Marsh, K; Des Jarlais, D; Uusküla, A; Lutsar, I (2013). Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug users. Infection,genetics and evolution, 20, 78 – 82.
Huik, K; Avi, R; Carrillo, A; Harper, N;Pauskar, M; Sadam, M; Karki, T; Krispin, T; He, W; Lutsar, I (2013). CCR5 Haplotypes Influence HCV Serostatus in Caucasian Intravenous Drug Users. PLoS ONE, 8(7), e70561
Lodi, S; del Amo, J; d’Arminio Monforte, A;Abgrall, S; Sabin, C; Morrison, C; Furrer, H; Muga, R; Porter, K; Girardi, E(2013). Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax, 68(3), 207 -213.
Touloumi, G; Pantazis, N; Pillay, D;Paraskevis, D; Chaix, ML; Bucher, HC; Kucherer, C; Zangerle, R; Kran, AM;Porter, K (2013). Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. Clinical Infectious Diseases, 56(6), 888 -897.
van der Helm, J; Geskus, R; Sabin, C; Meyer,L; Del Amo, J; Chene, G; Dorrucci, M; Muga, R; Porter, K; Prins, M (2013). Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after. Gastroenterology,144(4), 751 – 760.
2012
Huang, X.; Lodi, S.; Fox, Z.; Li, W.; Phillips,A.; Porter, K.; Lutsar, I.; Kelleher, A.; Li, N.; Xu, X.; Wu, H.; Johnson, AM.(2012). Rate of CD4 decline and HIV-RNA change following HIV Seroconversion inmen who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. Jaids-Journal of Acquired Immune Deficiency Syndromes
Jarrin, I; Pantazis, N; Gill, MJ; Geskus, R;Perez-Hoyos, S; Meyer, L; Prins, M; Touloumi, G; Johnson, A; Hamouda, O; deOlalla, PG; Porter, K; del Amo, J (2012). Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clinical Infectious Diseases, 54(1), 111 – 118.
2011
Avi, R; Huik, K; Pauskar, M; Ustina, V; Karki,T; Krispin, T; Ainsalu, K; Paap, P; Schmidt, J; Nikitina, N; Lutsar, I. (2011).EmergingTransmitted Drug Resistance in Treatment Naive Human Immunodeficiency Virus – 1CRF06_cpx Infected Patients in Estonia. Scandinavian Journal of Infectious Diseases, 43(2), 122 – 128.
Jaffe, HW; De Stavola, BL; Carpenter, LM;Porter, K; Cox, DR (2011). Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. AIDS, 25(11), 1395 – 1403.
Laisaar, K.-T.; Avi, R.; Dehovitz, J.;Uusküla, A. (2011). Estonia at the Threshold of the Fourth Decade of the AIDS Era inEurope. Aids Research and HumanRetroviruses, 27(8), 841 – 851.
Lutsar, Irja (2011). Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Archives of Internal Medicine, 171(17), 1560 – 1569.
Mussini, C; Cossarizza, A; Sabin, C; Babiker, A; De Luca, A; Bucher, HC; Fisher, M; Rezza, G; Porter, K; Dorrucci, M (2011). Decline of CD4(+) T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals. AIDS, 25(8), 1041 – 1049.
van der Helm, JJ; Prins, M; del Amo, J;Bucher, HC; Chene, G; Dorrucci, M; Gill, J; Hamouda, O; Sannes, M; Porter, K;Geskus, RB (2011). The hepatitis C epidemic among HIV-positive MSM: incidence estimatesfrom 1990 to 2007. AIDS, 25(8),1083 – 1091.
2010
Huik, K.; Sadam, M.; Karki, T.; Avi, R.;Krispin, T.; Paap, P.; Rüütel, K.; Uusküla, A.; Talu, A.; Abel-Ollo, K.;Lutsar, I. (2010). CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug users. The Journal of Infectious Diseases, 730 -739.
Avi, R.; Huik, K.; Sadam, M.; Karki, T.;Krispin, T.; Ainsalu, K.; Paap, P.; Schmidt, J.; Nikitina, N.; Lutsar, I.(2010). Characterization of Integrase Region Polymorphisms in HIV-1 CRF06_cpxViruses in Treatment Naïve Patients in Estonia. Aids Research and Human Retroviruses, 26(10), 1109 – 1113.
2009
Avi, R; Huik, K; Sadam, M; Karki, T; Krispin, T; Ainsalu, K; Paap, P; Schmidt, J; Nikitina, N; Lutsar, I. (2009). Absence of Genotypic Drug Resistance and Presence of Several Naturally Occurring Polymorphisms of Human Immunodeficiency Virus-1 CRF06_cpx in Treatment-Naive Patients in Estonia. Journal of Medical Virology, 81(6), 953 – 958.
2008
Bhaskarran, K.; Hamouda, O.; Sannes, M.;Bonfassa, F.; Johnson, A.M.; Lambert, P.C.; Porter, K.; CASCADE, Collaboration(2008). Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population. JAMA: the journal of the American Medical Association, 300(1), 51 – 59.
Jarrin, I.; Geskus, R.; Bhaskaran, K.; Prins, M.; Perez-Hoyos, S.; Muga, R.; Hernández-Aguado, I.; Meyer, L.; Porter, K.; del Amo, J.; Group author CASCADE Collaboration, (incl. I.Lutsar). (2008). Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. American Journal of Epidemiology, 168(5), 532 – 540.
Touloumi, G.; Pantazis, N.; Stirnadel, HA.;Walker, AS.; Boufassa, F.; Vanhems, P.; Porter, K. (2008). Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice. Jaids-Journal of Acquired Immune Deficiency Syndromes, 49(5), 492 – 498.
2005
Lutsar, I. (2005). HI-viirusinfektsioon kui globaalne probleem. Eesti Arst,4, 238 – 243.
